Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCRX.L Regulatory News (CRX)

  • There is currently no data for CRX

Directorate Change

25 Feb 2009 07:00

RNS Number : 8182N
Cyprotex PLC
25 February 2009
 



25 February 2009

Cyprotex PLC ('Cyprotex' or the 'Company')

Directorate changes

Cyprotex PLC (AIM: CRX) today announces the resignation of David Evans as a Non-executive Director of the Company with immediate effect and the appointment of John Dootson as Chief Financial Officer effective from 2 March 2009.

Commenting on the directorate changes, Steve Harris, Chairman of Cyprotex said: 

"David has made a significant contribution to the Company as a Non-executive Director and the Board would like to thank him for his contribution to the Company and wish him well with his future endeavours. 

The Company is very pleased to appoint John Dootson as Chief Financial Officer. John has been associated with the Company for over four years as a consultant Financial Controller and therefore has intimate knowledge of the Company's business and finances. He brings to the Company wide ranging financial expertise gained in both industry and private practice"

Notes for Editors: 

John Dootson, aged 47, has 25 years experience in both professional practice and in industry. Trained with Tenon and Ernst & Young, John has extensive managerial experience in major accounting practices and has worked on a wide range of projects including London Stock Exchange flotations and circulars, corporate governance, company acquisitions and disposals and specialist advice to growing SMEs. John has also worked in a number of roles in Industry at Financial Controller and Director level, including seven years within the senior head office finance team of BTP plc, a former FTSE250 specialty chemical manufacturer with over 50 sites worldwide prior to its sale to Clariant AG for £1.1bn.

John is a Fellow of the Institute of Chartered Accountants in England and Wales and for the last four years he has assisted Cyprotex in a management consultative role that has included all aspects of finance and reporting.

The following information relating to Mr. Dootson is provided in compliance with the provisions of Rule 17, Schedule Two, paragraph (g) of the AIM Rules for Companies

 

Full name and age: John Kevin Dootson, age 47.

Present directorships: Downham Mayer Clarke Limited

 

Directorships during the past five years:  Downham Mayer Clarke Limited

Mr. Dootson has not been a director of any company which has been wound up or placed in administration or receivership.

Mr. Dootson holds no shares in the Company. 

There are no further disclosures to be made in respect of Mr. Dootson under the provisions of Rule 17, Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

Enquiries:

Cyprotex PLC

 

Tony BaxterCEO 

01625 505100

Mark WarburtonCompany Secretary

 

Noble & Company Limited

 

John Llewellyn-Lloyd 

 02077632200

Sam Reynolds

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOATIMATMMITBJL
Date   Source Headline
18th Jun 20101:16 pmRNSHolding(s) in Company
21st Apr 20107:00 amRNSFrench Research Tax Credit Accreditation
15th Apr 20107:00 amRNSUS Business Development Executive Appointment
18th Mar 20107:00 amRNSEnd of Offer Period
17th Mar 20107:00 amRNSFinal Results
16th Mar 20106:10 pmRNSRule 8.3- Cyprotex PLC
3rd Mar 201010:06 amPRNRule 8.3 - Cyprotex
2nd Mar 201012:48 pmRNSRule 2.10 Announcement
2nd Mar 20107:00 amRNSStatement re Unsolicited Approach
17th Feb 20104:05 pmRNSNominated Adviser Change of Name
29th Jan 20107:00 amRNSTrading Statement
5th Jan 20107:00 amRNSTrading Update
25th Nov 200912:37 pmRNSDirector/PDMR Shareholding
20th Nov 20097:00 amRNSStatement re Trading
17th Nov 20092:37 pmRNSIssue of Equity
18th Sep 20094:29 pmRNSDirectors Dealing
12th Aug 20097:00 amRNSHalf Yearly Report
14th Jul 20098:00 amRNSAGM Statement
7th May 20097:00 amRNSLaunch of Cloe Gateway Web Portal
31st Mar 20097:00 amRNSAppointment of new CCO
17th Mar 20097:00 amRNSFinal Results
11th Mar 20093:39 pmRNSNotice of Results
6th Mar 20094:02 pmRNSHolding(s) in Company
25th Feb 20097:00 amRNSDirectorate Change
5th Feb 20097:00 amRNSChange of Adviser
23rd Jan 20097:00 amRNSTrading Statement
5th Jan 200912:55 pmRNSDirectorate Change
6th Nov 200812:42 pmRNSTrading Statement
5th Sep 20088:54 amRNSDirector/PDMR Shareholding
5th Sep 20087:30 amRNSDirector/PDMR Shareholding
29th Aug 200810:25 amRNSAppointment of New Chairman
28th Aug 20087:00 amRNSInterim Results
27th Aug 200812:52 pmRNSResult of Placing and Open Of
6th Aug 20084:04 pmRNSIssue of Equity
15th Jul 20082:25 pmRNSResult of AGM
14th Jul 200810:00 amRNSAGM Statement
24th Jun 20087:30 amRNSDirector resignation
20th Jun 20087:30 amRNSShare placement
19th Jun 200811:00 amRNSAnnual Report and Accounts
3rd Jun 20083:33 pmRNSAppointment of CEO
24th Apr 20087:00 amRNSPreliminary results
21st Apr 20087:30 amRNSPrelim results announcement
20th Mar 200812:47 pmRNSChairman appointment
25th Feb 20087:00 amRNSPartnership
20th Feb 20084:40 pmRNSHolding(s) in Company
21st Dec 20073:54 pmRNSDirector/PDMR Shareholding
17th Dec 20077:00 amRNSTrading Statement
30th Nov 20078:00 amRNSTotal Voting Rights
28th Nov 200711:11 amRNSDirector/PDMR Shareholding
23rd Nov 20071:50 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.